Immunologic and psychosocial status in chronic fatigue syndrome

Bratislava Medical Journal

Volumn 112, Issue 4, 2011, Pages 208-212

  Nas, K ^a   Cevik, R ^a   Batum, S ^a   Sarac, A J ^a   Acar, S ^a   Kalkanli, S ^a  

^a DICLE UNIVERSITY   (Turkey)

Author keywords

CD56; Chronic fatigue syndrome; Cytokines; Psychosocial status

Indexed keywords

CYTOKINE;

ADULT; ARTICLE; BLOOD; CHRONIC FATIGUE SYNDROME; DEPRESSION; FEMALE; HEALTH STATUS; HUMAN; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADULT; CYTOKINES; DEPRESSION; FATIGUE SYNDROME, CHRONIC; FEMALE; HEALTH STATUS; HUMANS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79953841386     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Levina PH, Whiteside TL, Braynt J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol 1998; 88: 96-104.
2. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE et al. Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988; 108: 387-439.
3. Fukuda K, Straus S, Hickie I, Sharpe Mc, Dobbins JG, Komarrof A. Chronic fatigue syndrome: A comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med 1994; 121: 953-959.
4. Masuda A, Nozoe SI, Matsuyama T, Tanaka H. Psychobehavioral and immunological characteristics of adult people with chronic fatigue and patients with chronic fatigue syndrome. Psychosoma Med 1994; 56: 512-518.
5. Swanink CM, Vercoulen JH, Galama JM, Roos MT, Meyaard L, van der Ven-Jongekrijg J, et al. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis 1996; 173: 460-463.
6. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol 1990; 28: 1403-1410.
7. Barker E, Fujimura SF, Faden MB, Landay AL, Levy JA. Immunologic abnormalities in chronic fatigue syndrome. Clin Infect Dis 1994; 18: S136-141.
8. Lloyd A, Hickie C, Dwyer J, Wakefield D. Cell-mediated immunity in patients with chronic fatigue syndrome, healthy control subjects and patients with major depression. Clin Exp Immunol 1992; 87: 76-79.
9. Chao CC, Janoff En, Hu SX, Thomas K, Gallagher M, Tsang M, Peterson PK. Altered cytokine release in peripheral blood mononuclear cell cultures from patients with the chronic fatigue syndrome. Cytokine 1991; 3: 292-298.
10. Landay Al, Jessop C, Lenette Et, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 1991; 338: 707-712.
11. Linde A, Anderson B, Svenson SB, Ahrne H, Carlsson M, Forsberg P, et al. Serum levels of lymphokines and soluble cellular recep tors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 1992; 165: 994-1000.
12. Gupta S, Aggarwal S, Star A. Increased production of interleukin-6 by adherent and non-adherent mononuclear cells during 'experimental fatigue' in patients with chronic fatigue syndrome. Int J Mol Med 1998; 209:209-213.
13. Papanicolaou DA, Wilder RL, Manologas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Int Med 1998; 128: 127-137.
14. Irwin M, Daniels M, Bloom ET, Smith TL, Weiner H. Life events, depressive symptoms, and immune functions. Am J Psychiatry 1987; 144: 437-441.
15. Hickie I, Lloyd A, Wakefield D, Parker G. The psychiatric status of patients with the chronic fatigue syndrome. Br J Psychiatry 1990; 156: 534-540.
16. Fukuda K, Straus S, Hicckie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-959.
17. Gur A, Cevik R, Nas K, Colpan L, Sarac S. Cortisol and hypothalamic-pituitary-gonadal hormones in follicular-phase women with fibromyalgia and chronic fatigue syndrome and effect of depressive symptoms on these hormones. Arthritis Research Therapy 2004; 6: R232-R239.
18. Hisli N. A validation study of Beck Depression Inventory. Turk J Psychol 1998; 6: 118-126.
19. Kücükdeveci AA, McKenna SP, Kutlay S, Gürsel Y, Whalley D, Arasil T. The development and psychometric assessment of the Turkish version of the Nottingham Health Profile. Int J Rehabil Res 2000; 23: 31-38.
20. Manu P, Matthews DA, Lane TJ, Tennen H, Hesselbrock V, Mendola R, Afleck G. Depression among patients with chief complaint of chronic fatigue. J Affect Disord 1989; 17: 165-172.
21. Stephen D, Shafran MD. The chronic fatigue syndrome. Am J Med 1991; 90: 730-739.
22. Gold D, Bowden R, Sixbey J, Riggs R, Katon WJ, Ashley R, et al. Chronic fatigue. A prospective clinical and virologic study. JAMA 1990; 264: 48-53.
23. Locke SE, Kraus L, Leserman J, Hurst MW, Heisel JS, Williams RM. Life change sress, psychiatric symptoms, and natural killer cell activity. Psychosom Med 1984; 46: 441-453.
24. Irwin M, Daniels M, Bloom ET, Weiner H. Life events, depression, and natural killer cell activity. Psychopharmacol Bull 1986; 22: 1093-1096.
25. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased natural killer activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis 1994; 18: S157-159.
26. Mawle AC, Nisenbuam R, Dobbins JG, Gray HE, Stewart JA, Reyes M. Immune responses associated with chronic fatigue syndrome: a case-control study. J Infect Dis 1997; 175: 136-141.
27. Tirelli U, Marotta G, Improta S, Pinto A. Immunological abnormalities in patients with chronic fatigue syndrome. Scand J Immunol 1994; 40: 601-608.
28. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis 1994; 18: S136-141.
29. Mihaylova I, DeRuyter M, Rummens JL, Bormans E, Meas M. Decreased expression of CD69 in chronic fatigue syndrome in relation to inflammatory markers: evidence for a disorder in the early activatias oft lymphoscytes and natural killer cells. Neuro Endoc Lett 2007; 28: 477-483.
30. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R_-targeted therapy (daclizumab) in multiple sclerosis. PNAS 2006; 103: 5941-594.
31. Prag S, Lepekhin EA, Kolkova K, Hartmann-Petersen R, Kawa A, Walmod PS, et al. NCAM regulates cell motility. J Cell Sci 2002; 115: 283-292.
32. Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, et al. Interleukin-lâ, interleukin-1 receptor antagonist, and souble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 1997; 17: 253-261.
33. Lloyd A, Gandevia S, Brockman A, Hales J, Wakefield D. Cytokine production and fatigue in patients with chronic fatigue syndrome and healthy control subjects in response to exercise. Clin Infect Dis 1994;18: S142-146.
34. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interactions with cellular sources and pattern of souble immune mediator expression. Clin Infect Dis 1994; 18: S147-S153.
35. Hickie I, Lloyd A. Are cytokines associated with neuro-psychiatric syndromes in humans?. Int J Immunopharmacol 1995; 17: 677-683.
36. Gupta S, Aggarwal S, See D, Starr A. Cytokine production by adherent and non-adherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 1997; 31: 149-156.